WallStSmart
JBIO

Jade Biosciences, Inc.

NASDAQ: JBIO · HEALTHCARE · BIOTECHNOLOGY

$24.13
-0.90% today

Updated 2026-06-03

Market cap
$1.01B
P/E ratio
P/S ratio
EPS (TTM)
$-2.63
Dividend yield
52W range
$7 – $28
Volume
0.7M

Jade Biosciences, Inc. (JBIO) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item202020212022202320242025
Revenue$0.00
Revenue growth (YoY)
Cost of revenue$1000.00$15000.00$68000.00$96000.00$282000.00$26000.00
Gross profit$-1000.00$-15000.00$-68000.00$-96000.00$-282000.00$-26000.00
Gross margin
R&D$7.94M$14.99M$38.62M$64.22M$53.19M$93.12M
SG&A$8608.00$20.42M
Operating income$-8.89M$-23.02M$-53.24M$-81.41M$-74.60M$-113.54M
Operating margin
EBITDA$-9.54M$-22.95M$-51.42M$-75.37M$-69.29M$-113.52M
EBITDA margin
EBIT$-9.54M$-22.96M$-51.49M$-75.47M$-69.57M$-113.54M
Interest expense$75000.00
Income tax$3000.00$25000.00$56000.00$55000.00
Effective tax rate0.0%-0.0%-0.0%-0.1%-0.1%0.0%
Net income$-9.61M$-22.96M$-51.51M$-75.52M$-69.63M$-127.41M
Net income growth (YoY)-138.9%-124.3%-46.6%+7.8%-83.0%
Profit margin

Frequently asked questions

How much free cash flow does JBIO generate?

JBIO produced $-94.89M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is JBIO's balance sheet healthy?

JBIO holds $88.44M in cash and equivalents against — in long-term debt, on $332.52M of shareholder equity. That debt is best read against the cash flow the business throws off each year.